Munich (ots/PRNewswire) - - Survey findings show that 97% of European cardiologists believe that non-valvular atrial fibrillation (NVAF) patients experience a delay in diagnosis,[1] which is associated with a higher risk of stroke[2] - European Cardiologists reveal the importance of reviewing patient ...
Lyon, France (ots/PRNewswire) - Clostridium difficile infection,a potentially fatal disease,[2]is at leasttwice as common as MRSA infections in hospitals[3],[4]and is estimated to cost the EU EUR3 billion per annum[5] A first of its kind expert consensus report on Clostridium difficile infection (CDI), contributed ...
London (ots/PRNewswire) - Loss of the ability to self-care and live independently are the most feared social-related outcomes of a stroke,[a] a survey of seven European countries reveals today on World Stroke Day. Yet only one in a hundred respondents surveyed were able to correctly identify all four main ways to ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - - Increases Non GAAP diluted earnings per ADS growth guidance to the high thirty percent range for the full year (2014). Shire announces unaudited results for the three months to September 30, 2014. Financial Highlights Q3 2014 Growth[1] $1,552 Product sales million +33%[2] $1,597 Total ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US- and UK-based media ESMO 2014 Abstract #: Physician biomarker survey: 1080O_PR; Erbitux: CRYSTAL: 541P; LASCCHN: 993PD; DIRECT: 996P; Pipeline: pimasertib: 443O; c-Met: 1333TiP, 450PD, 744TiP, 745TiP; further pipeline: 772P, 507PD, 1235P - New research ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage ...
Ballerup, Denmark (ots/PRNewswire) - Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK based media - Detailed 26-week results of SPARK study presented at SSIEM Annual Symposium - Phenylalanine tolerance significantly increased in children with PKU below 4 years of age, previously shown to be responsive to Kuvan and treated with Kuvan plus a ...
Calgary, Alberta (ots/PRNewswire) - In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. Resverlogix Corp. announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in ...
Beerse, Belgium (ots/PRNewswire) - New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide 'Tackling hepatitis C: Moving towards an integrated policy approach', a report published by The Economist Intelligence Unit (EIU) today reveals that many ...
Breakthrough Prize in Life Sciences Foundation
San Francisco (ots/PRNewswire) - Art Levinson Steps Down as Chair of Breakthrough Prize in Life Sciences Foundation, Succeeded by Cori Bargmann Online Nominations For 2015 Breakthrough Prizes in Fundamental Physics and Life Sciences are Open Through June 30, 2014 The Breakthrough Prize Foundation announces five winners of the inaugural Breakthrough Prize in Mathematics: Simon Donaldson, Stony Brook University and Imperial ...
Paris (ots/PRNewswire) - - In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi announced today full results from EDITION JP I and EDITION JP II that showed Toujeo(R) (insulin glargine ...
Bangalore, India (ots/PRNewswire) - The Infosys Board of Directors is pleased to announce the selection of Dr. Vishal Sikka as the Chief Executive Officer and Managing Director (CEO & MD) of the company. Dr. Sikka will be inducted as a whole-time director of the Board and CEO & MD (Designate) on June 14, 2014. He will take over as CEO & MD from Mr. S. D. Shibulal on ...
Darmstadt, Germany (ots/PRNewswire) - - Development and commercialization agreement on blood-based RAS biomarker mutation status test for (metastatic) colorectal cancer (mCRC) - This non-invasive, fast and easy-to-perform diagnostic test is expected to provide a real-time reflection of a patient's RAS mutation status to help guide clinical decision making in mCRC Merck ...
Chicago (ots/PRNewswire) - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC), demonstrate that the overall disease control rate was 94 percent for patients with EGFR T790M+ tumours - meaning that their ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of monotherapy ibrutinib showed continued ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Phase 3 data (Abstract LBA7008) featured in the official press programme of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine Data from the international, multicentre ...
LifeWatch AG / Key word(s): Strategic Company Decision/Quarter Results 27.05.2014 07:03 Release of an ad hoc announcement pursuant to Art. 53 KR ...
Beerse, Belgium (ots/PRNewswire) - - Research in haematological malignancies features VELCADE(R), siltuximab, ibrutinib and daratumumab - Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353, P960, P1211, P1209, P461, P356, P350, P434, P109 Janssen Pharmaceutica NV announced data related to ...
Toronto And Los Angeles (ots/PRNewswire) - Spin Master Ltd., Canada's largest children's toy and entertainment company and the world leader in flying toys, announced today that it has issued civil High Court proceedings against Character Options Ltd and Brix n' Clix (the "Defendants") in the High Court of Justice, ...
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract Number: 3506 - In a retrospective analysis of the Phase III CRYSTAL* study, which assessed RAS tumor status, significant clinical benefit was observed in mCRC patients with RAS wild-type tumors receiving Erbitux plus FOLFIRI, compared with FOLFIRI alone - No ...
Darmstadt, Germany (ots/PRNewswire) - - Primary endpoint met in SPARK study: significant increase in phenylalanine tolerance demonstrated after 26 weeks of the study in children less than 4 years of age with phenylketonuria and responsive to Kuvan treated with Kuvan plus a phenylalanine-restricted diet, versus diet alone - SPARK study was conducted as a post-authorization measure and results will be submitted to EMA this ...
Toronto And Los Angeles (ots/PRNewswire) - Spin Master Ltd., Canada's largest children's toy and entertainment company and the world leader in flying toys, announced today that it has filed a civil lawsuit against Brix n Clix, Rehco LLC and CYI Inc. (the "Defendants") in the United States District Court for the ...
Bangalore, India (ots/PRNewswire) - FY 14 revenue growth doubled to 11.5% in USD terms; Q4 operating margins expand 50 bps sequentially to 25.5%; Dividend pay-out ratio increased to 40% of post-tax profits; FY 15 revenues expected to grow 7%-9% in USD terms Financial Highlights Consolidated results under International Financial Reporting Standards (IFRS) for the year ...
Aachen/Brussels (ots) - Multi-stakeholder views on chronic pain presented in the European Parliament / Call to Action to fight chronic pain On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi- ...
Darmstadt, Germany (ots/PRNewswire) - - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or ...
Beerse, Belgium (ots/PRNewswire) - -- Addressing chronic diseases key to sustainable healthcare reform in Europe Janssen Pharmaceutica NV (Janssen) has commissioned a new report based on independent research by The Swedish Institute of Health Economics[1] presented alongside the 2014 EU Summit on Chronic Diseases in Brussels today. The 'Access to high-quality oncology ...
Munich, Germany (ots/PRNewswire) - For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased risk of stroke compared with the general population[2] Daiichi Sankyo today announced its commitment to extend the PREvention oF ...
Darmstadt, Germany (ots/PRNewswire) - - The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation - Study aims to recruit 946 patients across 17 European countries Merck, the global pharmaceutical and chemical company, today announced the enrollment of the first ...
Chertsey, England (ots/PRNewswire) - A recent study supported by an Astellas European Foundation Grant has identified potential therapeutic targets for transplantation treatment research. The study, carried out by Dr Nuria Lloberas, examined whether changing specific proteins in the body leads to a reduction in the immuno-inflammatory response thus lowering the risk of organ rejection. Dr Lloberas, from Hospital ...